J. T. Thiesing

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

K. Kolibaba, B. Druker, S. Ohno-Jones, 2000, Blood.

positive cells - other antileukemic agents against Bcr-Abl Efficacy of STI571, an Abl tyrosine kinase inhibitor, in conjunction with

K. Kolibaba, B. Druker, S. Ohno-Jones, 2013 .

Multimodal treatment of unresectable hepatocellular carcinoma to achieve complete response results in improved survival.

P. Newell, C. Hammill, R. Wolf, 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.